About GlucoTec
GlucoTec is a Healthcare company based in Greenville (United States) founded in 2005. It operates as a glycemic management system. GlucoTec has raised $15.94 million across 7 funding rounds from investors including Standard Pacific Capital. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices. Its legal entity is GLUCOTEC INC. Its competitors include Admetsys, TypeZero Technologies, Cellnovo, Pacific Diabetes Technologies and Ideal Medical Technologies and 3 more; 4 of its 8 listed competitors have raised funding.
Company details
GlucoTec was founded in 2005 in Greenville, United States, and operates within the healthcare sector. An eGlycemic Management System is provided, featuring FDA-cleared insulin dosing for intravenous and subcutaneous therapies across adult and pediatric populations. Integration with electronic medical records and devices supports inpatient, outpatient, and at-home care through telehealth and value-based programs. Systems can be deployed locally or remotely via the internet.
- Headquarters Greenville, United States
- SectorsHealthcare
- Website glucotec.com
- Legal Name Glucotec Inc
- Total Equity Funding$15.94M (USD)
in 7 rounds
- Latest Funding Round$3.5M (USD), Series A
Jul 2013
- Investors
Funding Insights of GlucoTec
GlucoTec has successfully raised a total of $15.94M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.94M
- Total Rounds 7
- Last Round Series A — $3.5M
- First Round $131,415
(Jul 2009)
- Investors Count 1
All 7 funding rounds of GlucoTec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2013 | $3.5M | Series A | – | – | – |
| Nov 2012 | $1.48M | Series A | – | – | – |
| Sep 2011 | $8.27M | Series A | – | Standard Pacific Capital | – |
| Jun 2011 | $2M | Seed | – | – | – |
| May 2011 | $462,150 | Seed | – | – | – |
| Dec 2010 | $100,000 | Seed | – | – | – |
| Jul 2009 | $131,415 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in GlucoTec
GlucoTec has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Standard Pacific Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | standardpacific.com | - |
Investor details for GlucoTec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GlucoTec
3 dated milestones of GlucoTec across 8 years, from founding to its latest funding, stage changes and deals.
- Founded GlucoTec is founded.
- Funding First funding round of $131K.
- Funding Latest funding round, Series A, of $3.5M.
Competitors of GlucoTec
GlucoTec has 8 listed competitors in our database, 4 of them funded. They include Admetsys, TypeZero Technologies, Cellnovo, Pacific Diabetes Technologies and Ideal Medical Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| admetsys.com | 2014 | Boston, United States | $50,000 | – | Provider of a closed-loop system for insulin and glucose delivery | |
| typezero.com | 2013 | Charlottesville, United States | $415,000 | – | Device for continuous glucose monitoring with manually operated insulin delivery | |
| cellnovo.com | 2002 | London, United Kingdom | $48.4M | – | Offers online slot gaming with bonuses, promotions, and secure interface. | |
| pacificdt.com | 2011 | Portland, United States | $6.52M | – | Electronic diabetes management device for glucose sensing and hormone delivery | |
| idealmedtech.com | 2013 | Asheville, United States | – | – | An AI-based artificial pancreas system is developed for ICU patients. | |
| animas.com | 1996 | West Chester, United States | – | – | Device for continuous glucose monitoring with manual insulin administration | |
| physiologicdevices.com | 2014 | Los Angeles, United States | – | – | Implantable insulin pump for diabetes treatment is being developed. | |
| pancreum.com | 2011 | San Francisco, United States | – | – | Develops modular drug delivery systems and automated insulin delivery solutions. |
Detailed competitors of GlucoTec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as GlucoTec (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glucotec
Complete news archive for GlucoTec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlucoTec
GlucoTec was founded in 2005 and raised its 1st funding round 4 years after it was founded.
GlucoTec is headquartered in Greenville, United States.
GlucoTec is a funded company, having raised a total of $15.94M across 7 funding rounds to date. The company's 1st funding round was a Seed of $131.42K, raised on Jul 2009.
GlucoTec was founded in 2005 in Greenville, United States, and operates within the healthcare sector. An eGlycemic Management System is provided, featuring FDA-cleared insulin dosing for intravenous and subcutaneous therapies across adult and pediatric populations. Integration with electronic medical records and devices supports inpatient, outpatient, and at-home care through telehealth and value-based programs. Systems can be deployed locally or remotely via the internet.
GlucoTec's top competitors include Admetsys, TypeZero Technologies and Ideal Medical Technologies.
GlucoTec has 1 investor. Key investors include Standard Pacific Capital.
GlucoTec operates through Glucotec Inc.